EGFR and non-small cell lung carcinoma: Smoking may hamper the efficacy of EGFR-TKIs in patients with EGFR-mutated NSCLC, and the overall effect of combination EGFR-TKI and anti-angiogenic agents in ever smokers showed significant improvement in the WJOG9717L, ETOP 10-16 BOOSTER, and BEVERLEY trials [29,30,31].